SynuCa Therapeutics
Copenhagen, Denmark· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing small molecule epigenetic therapies for cancer and neurodegenerative disorders.
OncologyNeuroscience
Technology Platform
A proprietary small molecule platform targeting epigenetic protein-protein interactions through structure-based drug design.
Opportunities
Potential to pioneer first-in-class therapies for diseases with limited treatment options by drugging challenging epigenetic targets.
Risk Factors
High technical risk associated with preclinical validation of novel epigenetic mechanisms and potential for unforeseen toxicities.
Competitive Landscape
Competes with larger firms like GlaxoSmithKline and Constellation Pharmaceuticals in epigenetics, but focuses on a distinct set of novel targets.